The goal of the Genomics Core is to provide comprehensive support for genomic analyses carried out in each of the Case Gl SPORE Projects. The Genomics Core will capitalize on the significant investment in common and shared infrastructure that has been created at CWRU, with support from the School of Medicine, the Case Comprehensive Cancer Center, and the Howard Hughes Medical Institute. CWRU and Cancer Center core resources that are part of this SPORE have been the subject of NIH support and are partially funded as such;thus, this SPORE will be leveraging the existing support to provide each project access to state-of-the-art genome-scale analysis expertise. The Genomics Core builds on exisfing core facilities that have a significant track record of performance and success, as well as the faculty interactions which have supported the initial work for components presented within each Project of this application. The Genomics Core will be a central resource for providing high-throughput genotyping and 'next-generation' DNA sequencing capability for two Projects. In addition, the Core will develop and implement additional methods as necessary to support all Projects, including Pilot Projects. The equipment and personnel available in the Genomics Core support research activities that require instrumentation and expertise that are not available or practical in the laboratories of the individual Project Pis, and for which centralized analyses are required in order to achieve process standardization and economies-of-scale. Specifically, the Genomics Core will perform region-specific DNA capture and high-throughput DNA sequencing and genotyping in support of the individual SPORE Projects. The Genomics Core will work closely with the Specimen and Tissue Core for access to quality assessment of materials for analysis and with the Biostatistics Core for data quality assessment and analysis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Yu, Ming; Maden, Sean K; Stachler, Matthew et al. (2018) Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut :
Berger, Nathan A (2018) New light on the pancreatic cyst conundrum. Transl Cancer Res 7:S545-S548
Sarvestani, Samaneh K; Signs, Steven A; Lefebvre, Veronique et al. (2018) Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoids. Oncotarget 9:28717-28730
Berger, Nathan A (2018) Young Adult Cancer: Influence of the Obesity Pandemic. Obesity (Silver Spring) 26:641-650
Moinova, Helen R; LaFramboise, Thomas; Lutterbaugh, James D et al. (2018) Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. Sci Transl Med 10:
Cooper, Gregory S; Markowitz, Sanford D; Chen, Zhengyi et al. (2018) Performance of multitarget stool DNA testing in African American patients. Cancer 124:3876-3880
Berger, Nathan A; Scacheri, Peter C (2018) Targeting Epigenetics to Prevent Obesity Promoted Cancers. Cancer Prev Res (Phila) 11:125-128
Cooper, Gregory S; Markowitz, Sanford D; Chen, Zhengyi et al. (2018) Evaluation of Patients with an Apparent False Positive Stool DNA Test: The Role of Repeat Stool DNA Testing. Dig Dis Sci 63:1449-1453
Somasundaram, Saigopal; Forrest, Megan E; Moinova, Helen et al. (2018) The DNMT1-associated lincRNA DACOR1 reprograms genome-wide DNA methylation in colon cancer. Clin Epigenetics 10:127
Codipilly, Don Chamil; Chandar, Apoorva Krishna; Singh, Siddharth et al. (2018) The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. Gastroenterology 154:2068-2086.e5

Showing the most recent 10 out of 141 publications